3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Palsy in 1 studies
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakshi, R | 1 |
| Faden, AI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dextromethorphan Versus Placebo for Neuropathic Pain[NCT00001344] | Phase 2 | 129 participants | Interventional | 1993-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Palsy
| Article | Year |
|---|---|
Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis.
Topics: Animals; Binding, Competitive; Dextrorphan; Dynorphins; Hindlimb; Male; Morphinans; Paralysis; Pepti | 1990 |